Comparable exposure is accomplished with subcutaneous administration of semaglutide while in the abdomen, thigh, or upper arm. Some reports propose that while the incidence of gastrointestinal adverse events is analogous to that of GLP-one receptor agonists, the dual system of action may well supply benefits when it comes to cardiovascular benef